Elevance Health, Inc. (ELV)
5 Stocks With Above-Market Yields Just Raised Payments Further
With the stock market going through its first earnings season of 2025, companies are making important announcements. This includes the approval of share buyback programs, as well as dividend increases.
Health-Tech Revival: 3 Stocks Set for a Big 2025 Rebound
The healthcare industry is undergoing rapid transformation, driven by advancements in technology, artificial intelligence, and data analytics. Companies at the forefront of this shift are redefining how healthcare providers manage data, deliver care, and enhance patient outcomes.
Elevance Health's Q4 Earnings Beat Estimates on Rising Premiums
ELV's fourth-quarter results benefit from rising premiums. However, higher expenses and attrition in Medicaid membership partially offset the positives.
Elevance Health Stock Rises as Company Tops Estimates, Raises Dividend
Shares of Elevance Health (ELV) advanced Thursday after the health insurance provider reported better-than-anticipated results on higher premiums, acquisitions, and growth of its pharmacy coverage unit. It also raised its dividend.
Elevance Health (ELV) Reports Q4 Earnings: What Key Metrics Have to Say
The headline numbers for Elevance Health (ELV) give insight into how the company performed in the quarter ended December 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Elevance Health Posts Q4 Profit Despite Medicaid Drop, Rising Costs; Hikes Dividend 5%
On Thursday, Elevance Health Inc. ELV reported fourth-quarter revenues of $44.99 billion, up 6% year-over-year, slightly higher than the consensus of $44.86 billion.
Elevance Health (ELV) Q4 Earnings and Revenues Beat Estimates
Elevance Health (ELV) came out with quarterly earnings of $3.84 per share, beating the Zacks Consensus Estimate of $3.80 per share. This compares to earnings of $5.62 per share a year ago.
Elevance Health Q4 2024 Earnings: Managed Care Continues To Impress
Despite a 29% drop in Elevance Health's stock, I maintain a strong buy rating due to a DCF price target of $549.60, indicating 43% upside. ELV's shift towards managed care, with strong industry tailwinds, supports sustainable margin expansion and revenue growth, making it a compelling investment. Regulatory risks around Pharmacy Benefit Management are mitigated by CarelonRx's diversified revenue streams and a healthy margin of safety in my modeling.
Elevance Stock Gains After Strong Quarter. A Dividend Hike Is Another Positive.
The health insurer's fourth-quarter adjusted earnings top analysts' estimates.
Elevance Health earnings boost health-insurance stocks after upbeat outlook
UnitedHealth, Humana and Centene all rally premarket
Elevance beats quarterly profit estimates on lower-than-expected medical costs
Elevance beat Wall Street estimates for quarterly profit on Thursday, as the health insurer spent less than expected on the medical costs of its members.
Elevance Health Q4 Countdown: Smart Move to Buy or Stick With Hold?
ELV's fourth-quarter earnings are likely to have benefited from growing premiums, partially offset by higher expenses.
